SCHEMBL3948017

SCHEMBL3948017

Cc1ccc(C(=O)O)cc1Nc1nccc(-c2cnccn2)n1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 11/20 0.56
BCR P11274 9/20 0.56
PDGFRA P16234 9/20 0.56
PDGFRB P09619 6/20 0.56
EGFR P00533 4/20 0.56
PRKCA P17252 4/20 0.56
NR1I2 O75469 1/20 0.55
ADORA3 P0DMS8 1/20 0.55
PTGS1 P23219 1/20 0.55
KDR P35968 1/20 0.55
CHRNA4 P43681 1/20 0.55
PDE3A Q14432 1/20 0.55
CAMKK2 Q96RR4 1/20 0.53
KIT P10721 3/20 0.48
JAK3 P52333 1/20 0.48
BTK Q06187 1/20 0.48
ITK Q08881 1/20 0.48
CAMK2D Q13557 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3359717 0.89 ABL1 (0.55) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL4373261 0.86 CAMKK2 (0.53) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL3359726 0.86 ABL1 (0.51) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL3359707 0.86 ABL1 (0.54) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL29707254 0.85 ABL1 (0.71) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL533540 0.85 ABL1 (0.71) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL22169828 0.85 CAMKK2 (0.59) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL22169842 0.84 CAMKK2 (0.63) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL3949460 0.83 CAMKK2 (0.53) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL22169873 0.82 CAMKK2 (0.74) ABL1BCRPDGFRAPDGFRBEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009109991-A2 NOVEL HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD., (IN) 2009-09-11 WO claimed
EP-1922309-B1 N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF IL YANG PHARM CO LTD (KR) 2014-05-21 EP disclosed
WO-2009109991-A2 NOVEL HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD., (IN) 2009-09-11 WO disclosed
US-7501424-B2 N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof IL-YANG PHARM. CO., LTD. (KR) 2009-03-10 US disclosed
EP-1922309-A1 N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF Il Yang Pharm. Co. Ltd. (KR) 2008-05-21 EP disclosed
US-20080096899-A1 N-Phenyl-2-Pyrimidine-Amine Derivatives and Process for the Preparation Thereof IL-YANG PHARM. CO., LTD. (KR) 2008-04-24 US disclosed
WO-2007018325-A1 N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF IL-YANG PHARM. CO., LTD. (KR) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096899-A1 N-Phenyl-2-Pyrimidine-Amine Derivatives and Process for the Preparation Thereof ITPA, TYMP, THPO ABL1 451/4885BCR 990/4885PDGFRA 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.